SMR 2022 - 2022 Society for Melanoma Research Congress
Oct 17 - Oct 20, 2022 | EdinburghUK
LARVOL is not affiliated with 2022 Society for Melanoma Research Congress and all trademarks, logos, and brand names are property of their respective owners
Condition
Stage
Treatment
Setting
Biomarker
Trial Name/ID
Showing 3 abstracts linked to Trials
LATE BREAKING ABSTRACT: Adjuvant therapy with nivolumab versus placebo in patients with stage IIB/C melanoma (CheckMate 76K)
LATE BREAKING ABSTRACT: Adjuvant pembrolizumab (pembro) in stage II melanoma: outcomes in histopathologic subgroups in the phase 3 KEYNOTE-716 study
Results from the randomized controlled phase 3 trial in PD-1 blockade refractory melanoma comparing ipilimumab to TIL therapy